Breast Cancer Treatments That Shut Down the Ovaries: What you need to know
One of the studies that has attracted the most attention at the 2014 American Society of Clinical Oncology Annual Meeting and in the media covering the meeting is a phase III trial that found giving a woman with hormone receptor negative (ER- and PR-) breast cancer goserelin (Zoladex), a drug that temporarily shuts down the ovaries, increased the odds that her ovaries would resume functioning after she completed treatment.